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In recent years, there has been growing interest in the area of 
open source software (“OSS”) as an alternative economic model.  
However, the success of the OSS mindshare and collaborative 
online experience has wider implications to many other fields of 
human endeavor than the mere licensing of computer programmes.  
There are a growing number of institutions interested in using OSS 
licensing schemes to distribute creative works and scientific 
research, and even to publish online journals through open access 
(“OA”) licenses.  There appears to be growing concern in the 
scientific community about the trend to fence and protect scientific 
research through intellectual property, particularly by the abuse of 
patent applications for biotechnology research.  The OSS 
experience represents a successful model which demonstrates that 
IP licenses could eventually be used to protect against the misuse 
and misappropriation of basic scientific research.  This would be 
done by translating existing OSS licenses to protect scientific 
research.  Some efforts are already paying dividends in areas such 
as scientific publishing, evidenced by the growing number of OA 
journals.  However, the process of translating software licenses to 
areas other than publishing has been more difficult.  OSS and OA 
licenses work best with works subject to copyright protection 
because copyright subsists in an original work as soon as it is 
created.  However, it has been more difficult to generate a license 
that covers patented works because patents are only awarded 
through a lengthy application and registration process.  If the open 
science experiment is to work, it needs the intervention of the legal 
community to draft new licenses that may apply to scientific 
research.  This article will look at the issue of such OA licenses, 
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paying special care as to how the system can best be exported to 
scientific research based on OSS and OA ideals.  
I. INTRODUCTION 
Recent years have witnessed an increase in the quantity and 
quality of studies dedicated to the economics of research and 
development for science and technology,2 with particular interest 
paid to the economic study of the impact of intellectual property 
rights in the fostering of innovation.3  Intellectual property (“IP”) 
has been considered one of the most important drivers of new 
innovation in science and technology because it allows researchers, 
institutions, and inventors to recover their investment in the shape 
of limited monopolies to their ideas.4  However, some authors have 
raised concerns that enhanced intellectual property protection may 
actually have adverse effects in the development of future 
research.5  Basic research had usually not been considered to be 
subject to protection, and up until recently it was generally offered 
to the public in the shape of peer-reviewed journals.  However, 
there is a growing trend towards excessive commercialisation and 
protection of scientific data, as illustrated in the case of the 
growing protection of the human genome.6  
                                                 
2 See, e.g., M. P. FELDMAN, A. N. LINK & D. S. SIEGEL, THE ECONOMICS OF 
SCIENCE AND TECHNOLOGY:  AN OVERVIEW OF INITIATIVES TO FOSTER 
INNOVATION, ENTREPRENEURSHIP, AND ECONOMIC GROWTH (Kluwer Academic 
2002). 
3 See OVE GRANSTRAND, THE ECONOMICS AND MANAGEMENT OF 
INTELLECTUAL PROPERTY:  TOWARDS INTELLECTUAL CAPITALISM (Edward 
Elgar ed., 1999); KEITH E. MASKUS, INTELLECTUAL PROPERTY RIGHTS IN THE 
GLOBAL ECONOMY (Institute for International Economics 2000).  
4 See, e.g., Edwin Mansfield, Patents and Innovation:  An Empirical Study, 32 
MGMT. SCI. 173 (1986). 
5 Steve Bunk, Researchers Feel Threatened by Disease Gene Patents, 13 THE 
SCIENTIST 7 (1999); J. H. Reichman & Paul F. Ulhir, Database Protection at the 
Crossroads:  Recent Developments and Their Impact on Science and 
Technology, 14 BERKELEY TECH. L.J. 793 (1999). 
6 John Sulston, Intellectual Property and the Human Genome, in GLOBAL 
INTELLECTUAL PROPERTY RIGHTS:  KNOWLEDGE, ACCESS, AND DEVELOPMENT 
61–73 (Peter Drahos & Ruth Mayne eds., 2002). 
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Because access to scientific data has become a requisite of 
modern research and development (“R&D”), there is growing 
concern that the trend towards commercialisation will translate into 
less available public academic research, which would therefore 
reduce the overall scientific output.  These worries have prompted 
several studies and reports that attempt to address the problem of 
the dissemination of academic scientific research.7  The area of 
biotechnology has been deemed to be of particular concern 
because of its significant economic potential; therefore, it has been 
the subject of a patenting rush of unprecedented proportions.8  This 
phenomenon has prompted the release of genetic information into 
the public domain, which has also prompted fears of the misuse of 
the publicly available data by unscrupulous users, who will use this 
information to close and commodify research through excessively 
general patents.  
These problems have motivated some to call for the devising 
and utilisation of new ways of protecting basic scientific research 
from potentially damaging commodification of knowledge.9  One 
proposed solution is to use the novel intellectual property licensing 
model that has been successful in software development, generally 
known as OSS.  This system uses intellectual property protection 
to ensure the wider dissemination of software, by maintaining the 
copyright protection over a work, and then distributing it using a 
license that allows further copying and redistribution of the work, 
ensuring that the wider community will have access to the 
                                                 
7 See, e.g., An Economic Analysis of Scientific Research Publishing, A Report 
Commissioned by the Wellcome Trust, Revised Edition (Oct. 2003), 
http://www.wellcome.ac.uk/assets/wtd003182.pdf; House of Commons Science 
and Technology Committee, Scientific Publications:  Free for All?, 2003–4, 
H.C. 399-I, http://www.publications.parliament.uk/pa/cm200304/cmselect/ 
cmsctech/399/399.pdf.  
8 GRAHAM DUTFIELD, INTELLECTUAL PROPERTY RIGHTS AND THE LIFE 
SCIENCE INDUSTRIES:  A 20TH CENTURY HISTORY 51–74 (Ashgate Publishing 
Limited 2003).  
9 Stephen  M. Maurer, New Institutions for Doing Science:  From Databases 
to Open Source Biology, paper presented to the European Policy for Intellectual 
Property Conference on Copyright and database protection, patents and research 
tools, and other challenges to the intellectual property system (Nov. 24–25, 
2003), http://www.merit.unimaas.nl/epip/papers/maurer_paper.pdf.  
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software’s source code and allow its modification and 
dissemination.  There are several open source and free software 
licensing models, but the common denominator in most of them is 
to allow access to the source code and to allow users to 
disseminate the code without restrictions.10  
It is with regards to scientific research and innovation that the 
possibility of translating some of these open source models to the 
scientific research arena comes into play.  The initial application of 
open source has been in the adoption of a scientific publishing 
model often referred to as OA.  The OA movement can best be 
exemplified by the publication of scientific outputs and other 
materials online.11  These results are offered online without 
subscription charges, allowing the wider scientific community 
access to high-quality content with the click of a button.  However, 
open access is not enough to ensure access to scientific works 
because OA generally covers only those materials that are subject 
to copyright protection, such as journal articles.  If scientists want 
to distribute their works using the open source model, then there 
would need to be some sort of license that allows the distribution 
of patented works, or works contained in scientific databases.  
The solution would appear to be a simple matter of translating 
existing licenses to protect patented research, but this has proven to 
be much harder than previously expected.12  It is very interesting 
that while there are new OA and open source licenses created 
every day, an open science license that protects research through 
patents and database rights has been slow in the making, despite 
                                                 
10 Andres Guadamuz, Viral Contracts or Unenforceable Documents? 
Contractual Validity of Copyleft Licenses, 26 EUR. INTELL. PROP. REV. 331 
(2004).  
11 Berlin Declaration on Open Access to Knowledge in the Sciences and 
Humanities, Conference on Open Access to Knowledge in the Sciences and 
Humanities (Oct. 20–22, 2003), http://www.zim.mpg.de/openaccess-berlin/ 
berlindeclaration.html. 
12 Kenneth Neil Cukier, Open Source Biotech:  Can a Non-Proprietary 
Approach to Intellectual Property Work in the Life Sciences? 1 THE ACUMEN J. 
LIFE SCI. (2003), available at http://www.cukier.com/writings/ 
opensourcebiotech.html. 
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the obvious enthusiasm from commentators, and extensive political 
will to generate such a license.13   
There are many reasons for the difficulties encountered.  Some 
have pointed out that the open source model does not work best 
with patented works,14 because the model appears to be in conflict 
with the public interest justifications for patents, which imply that 
inventors are expected to recoup the investment they have 
incurred.  It has also been remarked that the open source model 
works best with copyright works because they protect creations 
that are immediately awarded protection, while patented research 
requires a specific application to the research, making its 
dissemination through open licenses a more difficult endeavor.  
The present article tries to respond and contribute to these 
developments by examining of the existing scheme to determine 
the efficacy of the movement and its application to all sorts of 
scientific research outputs.  Then, the paper will present a 
suggestion for a new licensing model for patentable scientific 
research that allows access and dissemination to diverse fields of 
endeavor.  
II.  WHAT IS OPEN SOURCE?  
There is considerable discussion about the different definitions 
and variations of what is generally understood as open source 
software, particularly because there is currently a divergence of 
opinion between different camps in whether one should use the 
terms “open source” or “free software” to define the movements 
implicit in the permissive distribution of software.15  This is not the 
                                                 
13 Dan Burk, Open Source Genomics, 8 B.U.J. SCI. & TECH. L. 254 (2002).  
14 Robin Cooper Feldman, The Open Source Biotechnology Movement:  Is It 
Patent Misuse? (2004) (unpublished manuscript, on file with Vol. 6 of 
MINNESOTA JOURNAL OF LAW, SCIENCE & TECHNOLOGY), available at 
http://papers.ssrn.com/sol3/papers.cfm?abstract_id=545082. 
15 For one side of the debate, see Richard Stallman, Why “Free Software” is 
better than “Open Source” (1998), http://www.gnu.org/philosophy/free-
software-for-freedom.html.  This dispute has been exacerbated by the release of 
the latest version (version 3) of the influential General Public License (“GPL”).  
There seems to be a final split in the making between the open source and free 
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place to solve this dispute, but it should be said that agreeing on 
the terms is of significant importance to the nascent movement.  
Suffice it to say, there are different terms that can be used to 
describe the movement:  Free Software (“FS”), Open Source 
Software (“OSS”), Free Open Source Software (“FOSS”), Free 
Libre Open Source Software (“FLOSS”), Open Code,16 and non-
proprietary software.17  The reason behind the many different terms 
and definitions is mostly historical, and comes from the fact that 
each denomination, particularly FS and OSS, have become 
attached with specific philosophies and ideologies, and, moreover, 
each of these definitions will usually inform the type of licenses 
used to distribute the work.18  This work will use the term “open 
source software” when talking specifically about the many 
different licenses used in software development.  
In its widest possible sense, OSS is used to define a computer 
program that allows later modifications by the user or other 
developers by providing access to its source code19 through the use 
of a permissive license.  In this light, non-proprietary software is 
considered as such if it “is released with a license that would 
permit others to ‘fork’ the software and release their own modified 
versions without onerous restrictions, even though the copyright 
may remain in the hands of a single individual.  At least in theory, 
control has been conceded.”20  
                                                                                                             
software camps because Linus Torvalds has decided not to adopt the new 
version in the Linux Kernel.  For an earlier discussion about the GPL v3, see 
Robert W. Gomulkiewicz, General Public License 3.0:  Hacking the Free 
Software Movement’s Constitution, 42 HOUS. L. REV. 1015 (2005).  
16 This is the term preferred by Lessig to avoid the FS/OSS debate.  See 
LAWRENCE LESSIG, CODE AND OTHER LAWS OF CYBERSPACE 7 (Basic Books 
2000).  
17 This term is the term preferred by the author.  See Guadamuz, supra note 
10, at 332. 
18 LAWRENCE E. ROSEN, OPEN SOURCE LICENSING:  SOFTWARE FREEDOM AND 
INTELLECTUAL PROPERTY LAW 51–69 (1st ed. 2004). 
19 “Source code” are the programming statements in a programming language 
that exist before the program is compiled into an executable application.  The 
executable form of the software is generally known as the object code, and can 
only be read by the machine.  
20 Wikipedia.com, Proprietary Software (2002), http://en.wikipedia.org/wiki/ 
proprietary_software.  
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Beyond this basic definition, there are a few differences 
between the other terms, but they are generally referring to some 
core principles.  In the strictest sense, the FS concept is centred on 
the idea of developing programs and distributing them freely.21  
Stallman defines free software as having four basic freedoms:  the 
freedom to run the program; the freedom to study how the program 
works by giving access to the source code; the freedom to 
redistribute copies; and the freedom to improve and distribute 
improvements to the public.22  As understood by the proponents of 
free software, programmers and other developers can charge for 
the software if it is their desire to do so, but the same underlying 
freedom behind the software must exist either if it is acquired for a 
fee or if it is not.  The user must still be able to have all of the 
freedoms described, with access to the source code as the most 
basic requisite.23  
These freedoms are protected by the adoption of a restrictive 
licensing model that makes use of existing copyright legislation 
that guards the source code from proprietary software developers 
who want to copy it, adapt it and include it in their own programs.  
This licensing model is exemplified in the General Public License 
(“GPL”).24 
Open source is closely related to Free Software development, 
but it does contain a different emphasis about the freedoms 
involved.  The term open source was coined during a strategy 
meeting in February 1998 in Palo Alto California by a group of 
software developers with links to the Linux operating system.25  
The need to create a new term to define this viewpoint had become 
evident because, until then, the prevalent way to describe all output 
                                                 
21 Tony Stanco, We are the New Guardians of the World (2001), 
http://lwn.net/2001/0531/a/guardians.php3.  It is vital to note that the meaning of 
the word “free” in FS does not mean free as in having no price, but rather free as 
in “freedom,” or as it is often stated in OS and FS circles, free must be 
understood as in freedom, not as in beer.   
22 The Free Software Definition, http://www.fsf.org/philosophy/free-sw.html. 
23 Selling Free Software, http://www.gnu.org/philosophy/selling.html.   
24 The text of the GPL can be found at http://www.gnu.org/copyleft/gpl.html. 
25 Open Source Initiative, History of the OSI, http://www.opensource.org/ 
docs/history.html.  
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produced by the non-proprietary approach was by using the 
expression “free software,” based mostly on the FS philosophy 
described.  It was apparent to many software developers that this 
movement had a tarnished reputation in the business world as a 
result of the more radical ideas held by people linked to the FS.  
Open Source then is the opposite of “closed source,” the traditional 
proprietary approach to software development in the commercial 
world.  Closed source is software “in which the customer gets a 
sealed block of bits which cannot be examined, modified, or 
evolved.”26  The main idea behind open source is to provide 
software for which the source is available for examination, 
modification and peer-review.  The official definition of OSS came 
out of the original meeting, and was based on the Debian Free 
Software Guidelines, a licensing model that accompanies the 
Debian GNU/Linux system, a Linux distribution.27  This has 
generated an Open Source Definition (“OSD”), which includes a 
recommended set of clauses that an OSS license should contain.28  
These licenses are exemplified by the Berkley Software 
Distribution (“BSD”), the Apache License and the Mozilla Public 
License (“MPL”).29 
III. THE OPEN SCIENCE MOVEMENT 
It has become increasingly common to see the term “open 
source” used to describe all sorts of fields of study outside of the 
software arena that gave rise to the concept.30  The application of 
this term to other fields could be loosely described as the open 
licensing movement, which can be defined as the distribution of 
works protected through intellectual property with the use of 
                                                 
26 Keeping an Open Mind (Nov. 11, 2000), http://www.catb.org/~esr/ 
writings/openmind.html.  
27 The guidelines can be found at http://www.debian.org/social_contract.html 
#guidelines.  
28 The OSD can be found at Open Source.org, The Open Source Definition, 
http://www.opensource.org/docs/definition.php. 
29 A list of approved licenses can be found at http://www.opensource.org/ 
licenses/. 
30 See, e.g., Sara Boettiger & Dan Burk, Open Source Patenting, 1 J. INT'L 
BIOTECHNOLOGY L. 11 (2004); Burk, supra note 13.    
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permissive “some rights reserved” licenses based on the principles 
reflected in open source licenses and definitions.  Given the varied 
choice of terminology encountered in software development, the 
new licensing scheme could also receive different names, such as 
non-proprietary licenses, free licenses, or commons licenses.  
However, the preferred word to describe this disparate movement 
seems to be the use of the term “open.”  Superficially, there seems 
to be a good argument to choose the term “open source,” as it is 
the one that is more readily identifiable by the public as a 
description of non-proprietary software models.31  However, the 
term “open source” is problematic because the open source 
paradigm may not translate well into other fields because the 
original term was used to describe the availability of a computer 
programme’s source code.  Therefore, open source should not be 
used to identify licensing schemes that do not refer to software at 
all, and where there is no source code to be open.  For example, a 
recent article in The Economist asks:  “What does it mean to apply 
the term ‘open source’ in fields outside software development, 
which do not use ‘source code’ as a term of art?  Depending on the 
field in question, the analogy with source code may not always be 
appropriate.”32  
Despite these misgivings, there would appear to be almost 
universal agreement about using the word “open” to describe a 
philosophical movement that shares the principles and objectives 
of the two main non-proprietary software camps.  The use of these 
ideals in the area of scientific research presents the birth of a new 
movement that could be called “open science.”  This movement 
could be defined as the application of open source licensing 
principles and clauses to protect and distribute the fruits of 
scientific research.  This can be done by applying the OSS model 
to protect other works in areas as varied as biotechnology, 
biodiversity databases, traditional knowledge, and medical 
research.  Non-proprietary and OA models would be an excellent 
                                                 
31 As a measure of the prevalence of open source over other terms, Google 
throws 337,000 results for “non-proprietary,” 19,000,000 results for “free 
software,” and 23,600,000 for “open source.”  
32 An open-source shot in the arm? ECONOMIST, June 10, 2004, available at 
http://www.economist.com/displaystory.cfm?story_id=2724420. 
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option to maintain a body of technological knowledge that can be 
shared without fear of misappropriation by commercial interests, 
access to the protected technologies.  According to Maurer, open 
science is thus defined:  “Open science is variously defined, but 
tends to connote (a) full, frank, and timely publication of results, 
(b) absence of intellectual property restrictions, and (c) radically 
increased pre- and post-publication transparency of data, activities, 
and deliberations within research groups.”33 
The suggested definition of open science can be used to cover 
the many different types of scientific outputs described, but there 
are two main areas of output that are being discussed in the 
literature as subject to the potential adoption of open licenses.  
These are the scientific publishing and the scientific output, such 
as databases and patented inventions.  The first is embodied in the 
open access movement; the second is better exemplified in the so-
called open biotechnology movement.  
A.  Open Access 
The term “open access” has become prevalent in the literature 
in recent years to identify works that are freely available over the 
internet (using free in the “freedom” sense).  These works will 
generally be distributed by maintaining their copyright—although 
the term should be generic enough to define works that have been 
released into the public domain.  OA then will be any work that 
has been offered under a permissive license that allows the 
redistribution of the work.  
More specifically, OA has gained some very specific 
connotations because it is used to refer to academic journals and 
some forms of academic publication through the use of such 
licenses.  This is evidenced by the many different conferences and 
symposia that have been organised to provide a theoretical 
framework to OA, which has resulted in the influential Berlin 
Declaration on Open Access to Knowledge in the Sciences and 
Humanities,34 the Budapest Open Access Initiative (“BOAI”),35 the 
                                                 
33 Maurer, supra note 9. 
34 The full text of the declaration can be found at http://www.zim.mpg.de/ 
openaccess-berlin/berlindeclaration.html. 
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Bethesda Statement on Open Access Publishing,36 and also the 
European Cultural Heritage Online (“ECHO”) Charter.37  Of these, 
one of the most cited definitions is that of the Berlin Declaration, 
which defines open access as:  “a comprehensive source of human 
knowledge and cultural heritage that has been approved by the 
scientific community . . . .  Open access contributions include 
original scientific research results, raw data and metadata, source 
materials, digital representations of pictorial and graphical 
materials and scholarly multimedia material.”38   
This definition is very narrow, as it only accepts as OA those 
works approved by the scientific community, which seems to 
imply that a form of peer-review is required.  In similar fashion, 
the BOAI defines OA in light of peer-reviewed and scholarly 
publications, but it allows for the publishing of materials that have 
not been reviewed for the purpose of comments.  The BOAI states 
that OA covers literature which is published in “peer-reviewed 
journal articles, but it also includes any unreviewed preprints that 
they might wish to put online for comment or to alert colleagues to 
important research findings.”39  
Still, most of the definitions in the declarations tend to be very 
narrow.40  Philosopher and OA advocate, Peter Suber, proposes a 
more open definition, which states that: 
“Open access” (OA) is free online access.  OA literature is not only 
free of charge to everyone with an internet connection, but free of most 
copyright and licensing restrictions.  OA literature is barrier-free 
literature produced by removing the price barriers and permission 
                                                                                                             
35 More about the initiative can be found at Budapest Open Access Initiative 
(“BOAI”), http://www.soros.org/openaccess. 
36 See Bethesda Statement on Open Access Publishing, http://www.earlham. 
edu/~peters/fos/bethesda.htm.  
37 See European Cultural Heritage Online, http://www.ling.lu.se/projects/ 
echo/contributors/charter.html.  
38 See Berlin Declaration on Open Access to Knowledge in the Sciences & 
Humanities, supra note 11.   
39 BOAI, supra note 35 (follow hyperlink “read the initiative”).  
40 For another narrow definition, see Directory of Open Access Journals 
(“DOAJ”), http://www.doaj.org/articles/questions#definition. 
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barriers that block access and limit usage of most conventionally 
published literature, whether in print or online.41  
This definition tends to be more in line with the sharing ethos42 
that gives birth to open source software, and therefore it is more in 
line with the intellectual, legal, and ideological parent of open 
access.  While it must be said that there is an argument to be made 
in favour of quality control of scholarly research, the movement 
could benefit from further dissemination of other content offered 
online.  
The growth of OA journals is undeniable.  At the moment of 
writing, the Directory of Open Access Journals (“DOAJ”)43 listed 
almost 2000 OA journals in all categories of scientific research, 
with estimates that at least thirty new journals are being added to 
the DOAJ every month.  Figures such as these tend to indicate that 
this model may very well be the future of academic publishing, 
particularly for academic journals.  
Initially, one could be suspicious about the academic and 
economic viability of the model, but this is being disputed by the 
existing research.  Some studies, for example, indicate that journals 
that are available online have wider circulation and are more cited 
than more prestigious journals.  A study of 119,924 conference 
articles in computer science found that the most cited articles were 
significantly most likely to come from journals available online 
than from offline journals by an average of 336%.44  Another study 
in the United States has found that online journal publishing is 
economically sustainable under the present system because the 
revenue obtained by each published article from the publisher is 
equal to the cost of producing the article, which removes the 
economic recuperation justification.  The study points out that 
                                                 
41 Peter Suber, Creating an Intellectual Commons through Open Access (May 
28, 2004), http://dlc.dlib.indiana.edu/archive/00001246/01/suberrev052804.pdf. 
42 See Andres Guadamuz, The ‘New Sharing Ethic’ in Cyberspace, 5 J. 
WORLD INTELL. PROP. 129 (2002), http://papers.ssrn.com/sol3/papers.cfm? 
abstract_id=569111. 
43 See Nature WebDebates, http://www.doaj.org. 
44 Steve Lawrence, Free online availability substantially increases a paper’s 
impact, NATURE (May 31 2001), available at http://www.nature.com/nature/ 
debates/e-access/Articles/lawrence.html.  
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“[t]he monetary cost of the time that scholars put into the journal 
business as editors and referees is about as large as the total 
revenue that publishers derive from sales of the journals.”45  This 
statement is corroborated by more recent research that concludes 
that open source journals are increasing in numbers because they 
are able to be financed by different types of funding sources, 
including author fees, conference hosting, and the provision of 
value-added services.46  
B.  Open Biotechnology 
One of the best areas to explore the open science movement is 
the field of biotechnology research and the creation of open 
biotechnology, which can be defined as a sub-section of open 
science.  To understand the application of open source models to 
the field of biotechnology, one must understand the race to 
sequence the human genome.47  During the 1990s, there were 
several groups attempting to decode the human genome, but most 
of the public efforts were brought together in 1996 with the 
creation of the International Human Genome Sequencing 
Consortium (“the Consortium”), a collection of researchers from 
around the world.48  These efforts were geared towards the 
principle of sharing the information obtained by the participants 
with the common goal of classifying the totality of human genetic 
sequences, exemplified by the “Bermuda Principles.”49  The 
Principles clearly specified that the results of the research would be 
placed in the public domain as soon as possible.  The Human 
                                                 
45 Andrew Odlyzko, The Economics of Electronic Journals, 2 FIRST MONDAY 
(1997), available at http://firstmonday.org/issues/issue2_8/odlyzko/index.html. 
46 John Willinsky, Scholarly Associations and the Economic Viability of Open 
Access Publishing, 4 J. DIGITAL INFO. 177 (2003), available at http://research2. 
csci.educ.ubc.ca/eprints/archive/00000004/01/?printable=1.  
47 For a comprehensive account of the race for the human genome, see 
Sulston, supra note 6, at 61–73.    
48 These included the Wellcome Trust, the UK Medical Research Council, the 
U.S. National Center for Human Genome Research, the German Human 
Genome Programme, the European Commission, the Human Genome 
Organisation, and the Human Genome Project of Japan.  
49 For a summary of both meetings, see Doegenomes.org, http://www.ornl. 
gov/hgmis/research/bermuda.html. 
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Genome Organisation (“HUGO”) was made responsible for 
coordinating the data and for using the internet for its release.  
Despite the early spirit of sharing exemplified by the 
Consortium and by the Bermuda Principles, some firms started 
looking at the possibility of commercialising the results.  In 1998, 
a member of the Consortium created the company Celera 
Genomics, which set off immediately to finish a sequence of the 
human genome before the Consortium did.50  Celera eventually 
would fail in achieving the full genome first, even though there 
was growing suspicion that they were using parts of the publicly 
made material by the Consortium in order to boost their research.  
In the year 2000, a joint statement by the two participants was 
made public, announcing that there was an initial draft of the full 
human genome,51 and the results from the public sector have 
already been made public in several websites.52  However, in 2001 
the contending parties published their respective results at the same 
time, and while the Consortium claimed that Celera had copied 
their published results, Celera refuted the claims.53  Without going 
into the details of these controversial claims and counter-claims, it 
is clear that the race itself worried some public-sector researchers 
about the possible abuse of publicly available information that 
could be used later on to make broad patent claims and commodify 
the biological data offered.54  This fear seemed to be corroborated 
by the facts that by 1999, Celera had applied for the patenting of 
                                                 
50 Sulston, supra note 6, at 64–65.   
51 Human Genome Project, International Human Genome Sequencing 
Consortium Announces “Working Draft” of Human Genome, Human Genome 
Project press release, June 2000, http://www.nih.gov/news/pr/jun2000/nhgri-26. 
htm. 
52 A good collection of these can be found at http://www.ensembl.org/ 
index/html. 
53 To contrast both views, see R. Waterston, E. Lander & J. Sulston, On the 
sequencing of the human genome, 99 PROC. NAT’L ACAD. SCI. 3712 (2002); E. 
Myers et al., On the sequencing and assembly of the human genome, 99 PROC. 
NAT’L ACAD. SCI. 4145 (2002).  
54 Ken Howard, The Bioinformatics Gold Rush, 283 SCI. AM. 58 (2000), 
available at http://www.cvcaroyals.org/~rluker/pdf_files/Genomic_Business. 
pdf.  
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6500 human gene sequences, and by 2000 it had been awarded 300 
patents.55  
The state of affairs in biotechnology patenting generates 
considerable problems for those involved in this area, as excessive 
patenting threatens to hinder collaboration and research 
considerably because it generates an environment where 
researchers live in constant fear of litigation.  A study conducted in 
2002 found that researchers working in the area of genetics have 
significantly reduced normal academic collaboration practices due 
to fears about patent infringement, amongst other reasons.56  
Similarly, overly broad gene patents could be used to attempt 
to gain a foothold in the market and stifle competition in the 
nascent biotechnology industry.  Small research centres, 
educational institutions, and individual researchers may find it 
difficult to conduct research for fear of becoming involved in 
costly patent litigation.  Moreover, even if a biotechnology patent 
has been erroneously granted, stakeholders and researchers would 
still need to get involved in a lengthy procedure to cancel the 
invalid patent, further stifling research.57  A decrease in the practice 
of sharing biotech research could have nefarious consequences to 
the field, as the exchange of data held in different databases could 
be hindered.58  
This is where open biotechnology has been suggested as a 
possible tool to foster the exchange of research and the transfer of 
technology amongst researchers all over the world.  The general 
idea behind open biotechnology is to protect the fruits of scientific 
research by using non-proprietary licenses—particularly copyleft 
ones.  The research would be made available to the public online 
                                                 
55 Heather Kent, Benefits of genetic research must be shared, international 
genome organization warns, 162 CANADIAN MED. ASS’N J. 1736 (2000), 
available at http://www.cmaj.ca/cgi/reprint/162/12/1736. 
56 D. Blumenthal et al., Data Withholding in Academic Genetics, 287 J. AM. 
MED. ASS’N. 477 (2002).  
57 L. Andrews, The Gene Patent Dilemma:  Balancing Commercial Incentives 
With Health Needs, 2 HOUS. J. HEALTH L. & POL’Y 65 (2002).  
58 Nicholas Thompson, May the Source Be With You, WASHINGTON 
MONTHLY, (July/Aug. 2002), http://www.washingtonmonthly.com/features/ 
2001/0207.thompson.html. 
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with an attached license that allows further uses of the material, but 
forbids the commercialisation of the research by threatening to 
enforce the intellectual property rights that protect them.  This 
strategy would be compatible with the existing ethos of sharing 
research that exists in the scientific community.  Talking about the 
possible use of the open source model in the field of 
bioinformatics, scientist Ewan Birney from the European 
Bioinformatics Institute commented that “[f]or us, it’s straight 
scientific principles.  If you want to be a scientist, open up your 
data and open up the code that helps you work with that data.”59  
The first effort to implement this idea was undertaken by Tim 
Hubbard of the Sanger Institute in the United Kingdom, which was 
involved in the Human Genome Project.  Hubbard became 
interested in open source and open content licenses, until he 
realised that the model could be used to protect human genome 
research.60  Although Hubbard drafted a license, the idea was never 
implemented by the Sanger Institute because all of the materials 
were being released into the public domain and could not be 
licensed.  John Sulston, a prominent voice in the genetic research 
community, has provided some sobering comments about the fact 
that protecting scientific works intended for public dissemination 
with a license is contrary to the ethos behind such undertaking.61  
The idea is to make the works available to the public, not to tie 
them up in legal battles and complex patent suits. 
After this initial disappointment, there have been a few other 
suggestions about the use of the OSS model to protect the public 
results of the biotechnology research, although the implementation 
of such ideas has been minimal.62  The failure to produce a viable 
movement is made more evident when the open biotechnology 
idea is contrasted with the aforementioned open source software 
and OA models, which have been hugely successful by all 
                                                 
59 Sam Williams, I Hack the Body Electric, O’REILLY NETWORK, (July 25 
2002), http://www.oreillynet.com/lpt/a/2580. 
60 Cukier, supra note 12. 
61 Sulston, supra note 6, at 64. 
62 Burk, supra note 13.  
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measures.63  In contrast, the implementation of an open 
biotechnology or open health license has been slow.  There is no 
shortage of suggestions and positive press about the possibilities of 
open biotechnology, but these have not produced particularly 
concrete efforts.64  
Nevertheless, there is one particular area of open 
biotechnology that has been successful, and that is the area of 
bioinformatics.  Bioinformatics is the application of information 
technology to solve biological problems.65  Bioinformatics projects 
can use all sorts of software, but it has been increasingly likely to 
see open source software as a favoured tool.66  Nevertheless, the 
relative success of bioinformatics has more to do with the success 
of open source software than with the application of open 
biotechnology.   
Another success story in open science is the Center for the 
Application of Molecular Biology to International Agriculture 
(“CAMBIA”),67 which is an organisation that is attempting to solve 
many of the problems open science has faced by the judicious use 
of intellectual property “work-arounds” in the areas of agriculture, 
food security, biotechnology, and the environment.68  This is done 
through several IP specific proposals:  
                                                 
63 For more about the success of the movement, see STEVEN WEBER, THE 
SUCCESS OF OPEN SOURCE (Harvard Univ. Press 2004).  
64 See, e.g., R. Carlson, Open-Source Biology and Its Impact on Industry, 
SPECTRUM ONLINE, (May 2004), http://www.kurzweilai.net/meme/ 
frame.html?main=/articles/art0613.html. 
65 Wikipedia.com, “Bioinformatics,” http://en.wikipedia.org/wiki/ 
Bioinformatics. 
66 See, e.g., S. Dudoit, R.C. Gentleman & J. Quackenbush, Open source 
software for the analysis of microarray data, 34 BIOTECHNIQUES S45 (2003), 
available at http://papakilo.icmb.utexas.edu/cshl-2005/papers/Sandrine_ 
bioconductor.pdf; T. Hubbard et al., The Ensembl genome database project, 30 
NUCLEIC ACIDS RES. 38 (2002), available at http://nar.oxfordjournals.org/cgi/ 
reprint/30/1/38. 
67 The centre can be found at http://www.cambia.org. 
68 C. Dennis, Biologists launch 'open-source movement,’ 431 NATURE 494 
(2004).  
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(1) A portal called Biological Innovation for the Open 
Society (“BiOS”), which brings together a number of open 
biotechnology efforts.69 
The BiOS patent database includes 1,500,000 life-science 
patents from the different jurisdictions, which will allow 
researchers to look for possible patented materials in their 
area of research, allowing them to avoid costly litigation at 
a later date.70  
(2) CAMBIA has applied and obtained twelve patents of 
biologic material in different patent offices around the 
world.71  
(3) Bioinformatics tools offered through a research portal 
called BioForge.72  This repository will host diverse 
projects that operate in a similar manner to open source 
software projects, providing a place to bring together 
researchers. 
This is an encouraging step that will hopefully reverse the 
relative slow rate of progress in open biotechnology.  This is 
because there are now some workable licenses within the BiOS 
project.  These will be discussed in detail in the next section.  
IV. THE LICENSING PARADIGM  
One of the problems exposed by the open access debate is that 
there is significant misuse and misunderstanding of the terms and 
definitions involved.  It is common to read terms such as “free 
software,” “commons,” “open source,” and “public domain” 
interchangeably.  There must be an understanding that besides the 
ideological and philosophical connotations of each term, the heart 
                                                 
69 See CAMBIA, http://www.cambia.org/daisy/bios/home.html.   
70 See CAMBIA, Patent Lens, http://www.cambia.org/daisy/patentlens/ 
patentlens.html.   
71 CAMBIA, Intellectual Property, http://www.cambia.org/daisy/cambia/ 
intellectual_property.html. 
72 Based on the successful open source software project repository and portal 
called SourceForge.  BioForge can be found at https://www.bioforge.net/. 
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of the movement is the distribution of intellectual works through 
permissive licenses.  
The open licensing model is centered on the licenses; without 
them, the movement is just a project management technique.  The 
free software and open source software movements have shown 
the way to follow regarding licensing agreements.  The starting 
point for non-software licenses will be to learn from the 
experiences in non-proprietary software development.73  However, 
there should be an understanding that these licenses are just a 
starting point, as OSS licenses tend to be specific to software 
development and, in many instances, they have been drafted by 
software engineers with little or no intervention of the legal 
community.74  Furthermore, some software developers appear to 
display considerable reluctance about external intervention in the 
decision process regarding licensing decisions.75  This section takes 
a closer look at the attempts to translate the OSS ideals to the 
needs of scientific research.  
A.  Open Access Licenses 
Open access publishing tends to use “some rights reserved” 
licenses in order to distribute the academic materials involved.  
These may include the use of standard licenses, or in some 
instances, it may include the use of customised licenses.  At the 
                                                 
73 For literature that deals directly with FOSS licenses, see R. Gomulkiewicz, 
De-Bugging Open Source Software Licensing, 64 U. PITT. L. REV. 75 (2002); D. 
Ravicher, Facilitating Collaborative Software Development:  The Enforceability 
of Mass Market Public Software Licenses, 5 VA. J.L. & TECH. 11 (2000); D. 
Kennedy, A Primer on Open Source Licensing Legal Issues:  Copyright, 
Copyleft and Copyfuture, 20 ST. LOUIS U. PUB. L. REV. 345 (2001), available at 
http://law.slu.edu/journals/plr.html; C. Nadan, Open Source Licensing:  Virus or 
Virtue, 10 TEX. INTELL. PROP. L.J. 349 (2002). 
74 Richard Stallman is generally attributed as the author of the GPL, but 
Professor Eben Moglen provided legal assistance.  See GLYN MOODY, REBEL 
CODE:  LINUX AND THE OPEN SOURCE REVOLUTION 26 (Penguin 2002).  
75 Prodromos Tsiavos, The (dis)illusions of a rebel:  A reappraisal of the 
General Public License through techno-organizational analysis, Presented at the 
19th BILETA Annual Conference, University of Durham (Mar. 25–26, 2004).  
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time of writing, the most prevalent open access distribution scheme 
is through Creative Commons (“CC”) licenses.76  
The Creative Commons project attempts to create so-called 
“intellectual property conservancies,”77 separating a block of 
human knowledge offered for the benefit of the public, but still 
protected by intellectual property.  This is analogous to nature 
conservation areas that exist for the wider social benefit, but have 
restrictions on certain uses.  In the Creative Commons, the goal of 
intellectual property conservancies is achieved through the offering 
of a wide variety of licenses to protect creative works from misuse.  
This is done through the application of open source principles, 
where the work retains its copyright protection, but it is distributed 
freely78 as long as the conditions contained in the license are met.  
The interesting part of the CC licensing environment is that it 
empowers users because there is a wide range of licenses to choose 
from.  Creators and authors need only to go to a website and select 
from different options offered in a few drop-down menus; the 
system then chooses the license that fits the parameters entered.  
These licenses range from offering the work straight into the public 
domain, to more complex licenses with restrictions as to the 
commercial distribution of the work and the use of licenses in such 
distributions.79   
Creative Commons licenses maintain a minimum set of 
standards that are met by all of their offered legal documents, with 
the exception of the one that offers the work to the public domain.  
This could be called the Creative Commons Definition, but it is 
                                                 
76 For example, the Public Library of Science (“PLoS”), one of the largest 
open access journal collections, is published through a CC license. 
77 Creative Commons, Legal Concepts, http://creativecommons.org/learn/ 
legal/.  
78 In the Free Software sense.  
79 For more about Creative Commons, see Charlotte Waelde, et al., The 
Common Information Environment and Creative Commons, Final Report to the 
Common Information Environment Members of a study on the applicability of 
Creative Commons Licences (2005), available at http://geeklawyer.org/ 
ccreport.pdf.  
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generally known as the CC Baseline Rights.80  All CC licenses 
provide these baseline rights:  
Licensors retain their copyright; this explains why the baseline rights 
do not apply to public domain offerings.    
The licenses announce that fair use rights are not affected by the 
license.  This is a curious statement, as it should be assumed that any 
clause that erodes acquired fair use or fair dealing rights should be 
specified in the license. 
Licensees will have to obtain specific permission to perform one of the 
acts restricted by the license.  For example, if the license does not allow 
modification or adaptation of a work, this action could only be 
performed with the permission of the owner.  This seems to be a 
redundant statement, as this is an action that is usually understood in all 
licenses.  
Copyright notices should not be removed from all copies of the work. 
Every copy of the work should maintain a link to the license. 
Licensees cannot alter any terms of the license.  This seems to be yet 
another redundant clause, as it should be understood that this is 
common licensing practice.  
Licensees cannot use technology to restrict access to the work.  This 
baseline right specifically forbids the use of technical protection 
measures.81  
Licensees are granted the right to copy, distribute, display, digitally 
perform and make verbatim copies of the work into another format.  
The licenses have worldwide application, last for the entire duration of 
copyright (unless otherwise specified), and are irrevocable.82  
It is important to note that the baseline definition of CC 
licenses does not mention anything about modification or 
adaptation of a work, does not deal with copyleft-like clauses 
requiring the use of similar licenses to distribute the work, does not 
mention attribution, and does not deal with the distribution of 
copies for commercial purposes.  This makes the basic Creative 
Commons definition more akin the open source ideals than to the 
                                                 
80 See Creativecommons.org, Baseline Rights, http://creativecommons.org/ 
about/licenses/ [hereinafter Baseline Rights]. 
81 For more about technical protection measures, see Severine Dusollier, 
Electrifying the Fence:  The Legal Protection of Technological Measures for 
Protecting Copyright, 21 EUR. INTELL. PROP. REV. 285 (1999).     
82 See Baseline Rights, supra note 80.   
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free software principles exemplified by the GPL.83  Nevertheless, 
creators can choose a CC license that maintains all of the 
restrictions mentioned, from all of the options offered.  Authors 
then can choose from the following options to generate their 
license:84 
Attribution:  The work is made available to the public with the baseline 
rights, but only if the author receives proper credit.85    
Non-commercial:  The work can be copied, displayed and distributed 
by the public, but only if these actions are for non-commercial 
purposes.  
No derivative works:  This license grants baseline rights, but it does not 
allow derivative works to be created from the original.  
Share-Alike:  This is based on copyleft principles.  Derivative works 
can be created and distributed based on the original, but only if the 
same type of license is used, which generates a viral license.86  
It is possible to have licenses that combine several of these 
options.87  The strongest (and most popular) CC license is the 
Attribution Non-Commercial Share Alike License,88 which is the 
license that most resembles the strongest copyleft software ones 
(such as the GPL).  All CC licenses are presented in three formats:  
the first is a short and easy to read “Commons Deed,” which 
explains the terms and conditions of the license in a simple 
manner; the second format is the “Legal Code,” which is the full 
license; and the third is the “Digital Code,” which provides an 
HTML version of the license89 that can be read by search engines 
                                                 
83 Guadamuz, supra note 10, at 333–34. 
84 For more about the CC license elements, see http://creativecommons.org/ 
about/licenses.   
85 Starting with Creative Commons version 2.5, the Attribution element is 
factually a baseline right and not an element that can be chosen or not.  See 
Creativecommons.org, Choosing a License, http://creativecommons.org/ 
about/licenses/.  
86 For more about the concept of viral contracts, see Margaret Jane Radin, 
Humans, Computers, and Binding Commitment, 75 IND. L.J. 38 (2000).  
87 However, the No Derivative and the Share-Alike elements are exclusive.  
88 Version 2.0 can be found at Creative Commons.org, Commons Deed, 
http://creativecommons.org/licenses/by-nc-sa/2.0/. 
89 To be more specific, the code uses Resource Description Framework 
(“RDF”) metadata.  For more about RDF, see W3C Technology and Society 
Domain, Resource Description Framework (RDF), http://www.w3.org/RDF/. 
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and makes it easier to list the content in the Creative Commons 
directory.  
Creative Commons presents a very positive step towards the 
wider distribution of non-proprietary technology.  It is innovative, 
thoroughly planned and smartly implemented.  CC delivers open 
access licenses in the digital domain with scalability, adaptability, 
and ease of use for those unfamiliar with the legal issues involved 
in licensing.  CC also offers jurisdiction-specific versions of their 
licenses to make them more valid in an international environment 
and to respond to legal requirements in a given country.   
The other major open content license is the GNU Free 
Documentation License (“GFDL”),90 which is the FSF’s non-
software license, and it is generally used to protect manuals and 
other literature related to the FS movement.  However, the GFDL 
is also used in other open access projects, such as the free online 
encyclopedia Wikipedia.  The GFDL could be classified as an 
open access license because it allows the copying, distribution and 
adaptation of a work, provided the author complies with the 
conditions included.  These can be found in section two of the 
license, which states:  
You may copy and distribute the Document in any medium, either 
commercially or noncommercially, provided that this License, the 
copyright notices, and the license notice saying this License applies to 
the Document are reproduced in all copies, and that you add no other 
conditions whatsoever to those of this License.91 
This is an important point of the license, because it specifies 
that it allows for the commercial use of the works.  The GFDL 
allows for the modification and translation of the work, provided 
some specific sections are maintained or deleted; and all derivative 
works must be licensed using the GFDL.92  This clearly means that 
this is a copyleft license, perpetuating itself through this viral 
clause.  The viral nature of the license exists in section 4, which 
states that “[y]ou may copy and distribute a Modified Version of 
                                                 
90 The full text of the license can be found at The GNU Operation System, 
GNU Free Documentation License, (“GFDL”) http://www.gnu.org/copyleft/ 
fdl.html. 
91 Id. § 2.   
92 Id. § 4.   
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the Document . . . provided that you release the Modified Version 
under precisely this License . . . .”93  This is different from the 
share-alike element in CC licenses, as these require only that the 
work is released with a license that contains similar clauses and 
rights.   
The viral nature of the GFDL can be seen in practice through 
the wide copying and dissemination of Wikipedia articles, which 
are being used by many other open content providers, such as the 
Free Dictionary.94  The articles found in this online resource have 
to be licensed through the GFDL, allowing yet another third party 
to copy them and use them in their website, provided that they use 
the GFDL.  
With so many creative works that may be subject to protection 
by OA licenses, it should come as no surprise that there has been a 
recent proliferation of licenses that allow commercial and non-
commercial content creators to adopt the non-proprietary open 
access model.  One such project is the Open Content License 
(“OPL”), a collaborative effort that sets a copyleft license, 
ensuring that shared works will continue to remain free to 
subsequent users.95  Similar efforts also include music creation via 
the Open Audio License (“OAL”),96 the SCRIPT-ed Open License 
(“SOL”),97 and even Open Cola, the world’s first copyleft fizzy 
drink.98  
Looking at the vibrant nature of the OA movement and the 
publication of scientific materials in journals or through other 
online means, it is clear that there are enough reasons to believe 
that some part of the open science movement is doing quite well 
                                                 
93 Id.   
94 See The Free Dictionary by Farlax, http://encyclopedia.thefree 
dictionary.com/. 
95 The license can be found at Open Content License (“OPL”), 
http://www.opencontent.org/opl.shtml. 
96 See Electronic Frontier Foundation—Defending Freedom in the Digital 
World, http://www.eff.org/IP/Open_licenses/eff_oal.php.  
97 See SCRIPT-ed Open Licence (“SOL”), http://www.law.ed.ac.uk/ahrb/ 
script-ed/sol.htm. 
98 See Graham Lawton, The Great Giveaway, NewScientist.com, available at 
http://www.newscientist.com/hottopics/copyleft/copyleftart.jsp. 
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through the creation of growing body of work that is easily 
accessible to researchers around the world.  However, what 
happens with scientific research that is not subject to publication?  
Can scientific databases, archives, repositories, and patented 
research be protected through open licenses?   
B.  Open Science Licenses 
All of the aforementioned licenses have one thing in 
common—they protect only works that are subject to copyright.  
This is valuable when one considers that a significant amount of 
basic scientific works is protected by copyright, particularly 
academic journal articles and other literary works.  This raises the 
question of whether there can be open licenses that protect other 
types of work in commercially viable fields like biotechnology and 
health research—which are usually available through databases or 
patents.  This has proven to be difficult because, although there 
have been many scientists and researchers advocating the 
implementation of open licensing models to the scientific arena, it 
is difficult to find a patent or database equivalent to the GFDL or 
the Creative Commons licenses.  
The reason for this is that the open license model works better 
with copyright than with patents or databases.  There are two main 
reasons for this.  First, copyright subsists in an original work as 
soon as it is fixed in tangible form.99  Second, copyright does not 
require any sort of registration to initiate protection, which means 
that copyright “flows from the nib of a pen,”100 making it much 
easier and cheaper to distribute through an open license as soon as 
it is originated.  On the other hand, works that require registration 
to be subject to protection—such as patentable scientific 
research—will be more difficult to distribute through an open 
license, as several steps are required to distribute it with some sort 
of permissible licensing model. 
                                                 
99 Berne Convention on Literary and Artistic Works, art. 2 (Sept. 9, 1886) 
available at http://www.law.cornell.edu/treaties/berne/overview.html. 
100 P. Cohen & T. Ryan, Copyright Law and the Internet, http://info.utas.edu. 
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Although the specific difficulties of providing a patent solution 
will be discussed in more detail later, there has been some success 
in applying limited open science solutions for databases and 
patented works.  These efforts are listed next.  
1.  Database Licenses 
The importance of scientific databases for research is an issue 
that has been well explored in the existing literature.101  There can 
be little doubt that in the information age, access to the vast 
amount of scientific data stored in databases is of utmost 
importance for researchers around the world.  Access to a large 
number of databases is offered for a fee by a vast array of service 
providers and institutions.102  The growth in the number and the 
economic importance of scientific databases has been accompanied 
by increased concerns about the reuse of the data to provide further 
works of commercial value.  A report by the National Research 
Council in the United States points out that: 
Currently many for-profit and not-for-profit database producers are 
concerned about the possibility that significant portions of their 
databases will be copied or used in substantial part by others to create 
“new” derivative databases.  If an identical or substantially similar 
database is then either redisseminated broadly or sold and used in direct 
competition with the original rights holder's database, the rights 
holder’s revenues will be undermined, or in extreme cases, the rights 
holder will be put out of business.  Besides being unfair to the rights 
holder, this actual or potential loss of revenue may create a disincentive 
to produce and then maintain databases, thus reducing the number of 
databases available to others.103 
This is of particular worry for those who are releasing genetic 
data into the public domain, as described earlier.  With publicly 
available databases, commercial providers would find large 
sections of readily available information that can be repackaged 
                                                 
101 See, e.g., William M. Gelbart, Databases in Genomic Research, 282 
SCIENCE 659 (1998); Steve Lawrence & Lee Giles, Accessibility of Information 
on the Web, 400 NATURE 107 (1999).  
102 See NATIONAL RESEARCH COUNCIL, A QUESTION OF BALANCE:  PRIVATE 
RIGHTS AND THE PUBLIC INTEREST IN SCIENTIFIC AND TECHNICAL DATABASES, 
40–51 (National Academy Press 1999).  
103 Id. at 14.  
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and resold as part of a commercial database.  This possibility is 
precisely what has prompted the calls to protect databases through 
open source licenses.104  
Despite the suggested application of the open source licenses 
and ideals to databases, the actual application has not been met 
with the enthusiasm that it deserves, which can be explained by 
two main reasons.  Firstly, most non-commercial information—
particularly in the field of biotechnology—is released into the 
public domain.105  This type of release is extremely useful for 
future researchers, but it does little to curb the further 
commercialisation of the data.  
Secondly, the legal protection of databases is a subject that is 
not fully harmonised at the international level, where different 
jurisdictions apply a wide range of legal figures and levels of 
protection to this type of intellectual work.  For example, the 
United States106 has been struggling with the application of 
copyright law to the subject of databases by extending the 
definitions of originality of a work.  Earlier cases declared that the 
mere rearrangement of information was not enough to prove 
originality.107  Despite the originality requirement, there are 
circumstances where the courts will award copyright protection to 
databases due to the fact that there is enough originality in what is 
done to the data.108  Europe has followed a different path by 
embracing a “sweat of the brow” approach, where the work and 
investment that goes into the gathering and arranging of the data is 
rewarded, even if the data itself is not original,109 which is 
                                                 
104 Maurer, supra note 9.  
105 See, e.g., The GDB Human Genome Database, http://gdbwww.gdb.org/. 
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109 For more about database protection in Europe, see Catherine Colston, Sui 
Generis Database Right:  Ripe for Review?, 3 J. INFO. L. & TECH. (2001), 
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particularly evident with the European Directive on the legal 
protection of databases.110  The Directive awards a sui generis right 
to databases in which there has been a quantitative and qualitative 
investment in obtaining or verifying the contained data.111  
However, this picture is made more complex by the recent rulings 
from the European Court of Justice,112 which have eroded the 
database right considerably.  To further erode the European 
database right, a report by the European Commission about the 
application of the right has produced negative results, and even the 
call to potentially eliminate it.113   
It is precisely this complicated legal landscape that makes the 
possible application of open source software models so difficult for 
databases.  It would seem possible that providers of scientific data 
contained in a database compiled in a country that provides for the 
copyright protection of databases (such as the United States), may 
be able to issue their work through an open access license, perhaps 
even a Creative Commons license.  This would be possible 
because in most jurisdictions databases are protected as literary 
works.114  However, those providers would first have to be able to 
be awarded protection in the first place, which is not always the 
case, as evidenced by the originality standards prevalent in the 
United States.  In countries with a sui generis right, the licensing 
would have to meet with the very high requirements of the recent 
cases and the directive, which is not an easy task.  According to 
Waelde and McGinley:  
                                                 
110 DIRECTIVE 96/9/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL, 
Mar. 11, 1996, O.J. (L 077) (1996).  
111 Id. at art. 7(1).  
112 See Case C-203/02, British Horseracing Bd. v. William Hill, (2004) 
E.C.R.; Case C-338/02, Fixtures Mktg. Ltd. v. Svenska Spel, (2004) E.C.R.; 
Case C-46/02, Fixtures Mktg. Ltd v. OY Veikkaus, (2004) BAILII; Case C-
444/02, Fixtures Mktg. Ltd. v. OPAP, (2004) BAILII.    
113 European Commission, First Evaluation of Directive 96/9/EC on the Legal 
Protection of Databases (Dec. 2005), http://europa.eu.int/comm/internal_ 
market/ copyright/docs/databases/evaluation_report_en.pdf. 
114 See, e.g., Copyright, Designs and Patents Act, 1988, § 3A (U.K.); Berne 
Convention, supra note 99, at art. 2.5.     
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Suffice it to say many questions remain over the extent to which 
scientific databases might qualify for the sui generis right.  Whereas at 
first blush it might have appeared that many might fall out with the 
necessary criteria, . . . it is far too early to argue that the contents of 
scientific databases fall into the public domain as a result of the ruling, 
however much that might benefit scientists and the progress of 
science.115   
Taking into consideration all of these difficulties, it should 
come as no surprise that a large amount of online scientific data is 
still released into the public domain.  Nevertheless, there are 
indications that the solution may not be found in database 
protection, but in contractual law.  This is best evidenced by the 
International HapMap Project Public Access License 
(“HPPAL”),116 which is part of the HapMap genetic database 
project.  Unlike all other open licenses, the HPPAL does not assign 
any intellectual property rights; it is an end-user agreement.  The 
data can only be accessed through following a registration process, 
where the user is required to agree to terms and conditions before 
gaining access to the certain parts of the HapMap genetic database.  
The wording of the HPPAL makes it appear to be an 
intellectual property assignment of rights (it is after all, called a 
license), but it is not entirely clear what rights are held over the 
data that is being offered.117  The HPPAL is very careful not to 
assign intellectual property rights, so it must be assumed that this is 
just a user agreement where the author enters into the obligation to 
comply with the terms and conditions set out in the document.  
Specifically, paragraph three of the license states that:  “[y]ou may 
not access, copy, modify, sublicense, distribute or otherwise use 
                                                 
115 Charlotte Waelde & Mags McGinley, Public Domain; Public Interest; 
Public Funding:  Focusing on the ‘Three Ps’ in Scientific Research, (2:1 
SCRIPT-ed 83, 91 (2005)), available at http://www.law.ed.ac.uk/ahrb/script-
ed/vol2-1/3ps.asp. 
116 To view the license, see International HapMap Project, http://www. 
hapmap.org/cgi-perl/registration. 
117 For more about genetic database protection, see Edward Baba, From 
Conflict to Confluence:  Protection of Databases Containing Genetic 
Information, 30 SYRACUSE J. INT’L L. & COM. 121 (2003). 
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the Genotype Database or the data contained in it except as 
expressly provided under this License.”118  
The most relevant part of the HapMap license is with regards 
to future patent applications.  Paragraph 2(b) of the license does 
not allow the patenting of genetic information from the database, 
with the exception of particular uses of sequences, provided that 
the patent allows further use of the information obtained from the 
database.  The paragraph reads: 
[Y]ou shall not file any patent applications that contain claims to 
particular uses of any SNP, genotype or haplotype data obtained from 
the Genotype Database or any SNP, haplotype or haplotype block 
based on data obtained from, the Genotype Database, unless such 
claims do not restrict, or are licensed on such terms that that they do not 
restrict, the ability of others to use at no cost the Genotype Database or 
the data that it contains for other purposes; . . . .119 
This is an attempt to provide a viral or share-alike element to 
the agreement, as if the freedoms protected by this license are 
protected in the future licensing of patented material.  The 
HapMap license offers an ingenious way of getting around the 
problems of database protection enumerated above, as it relies on 
contractual obligations rather than on intellectual property 
protection, and may prove to be the way to go as far as database 
licenses are concerned.  
2.  Patent Licenses 
If the application of open licensing to scientific databases has 
been minimal, the porting of OSS licenses to patented research has 
been almost nonexistent and doubly problematic for reasons that 
will be explored in more depth in the next section.  Nevertheless, 
there have been a handful of attempts to provide a workable 
license for patented material, including a recent draft license.  
One of the most promising efforts to provide a license has been 
put forward by the Creative Commons project.  Because Creative 
Commons licenses are geared specifically towards creative works 
subject to copyright protection, a new concept has been designed 
                                                 
118 HapMap Project Public Access License, supra note 116, at para. 3.   
119 Id. at para. 2(b).   
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to accommodate scientific research.  This concept is the Science 
Commons project,120  which has been created to generate licenses 
that will deal with intellectual property works that are not covered 
by existing CC licenses.  The project is ongoing at the time of 
writing, and it has yet to produce a license draft available to the 
public.  
Another proposal is offered by Hubbard and Love, who explore 
some alternative models of pharmaceutical research and 
development to produce new medicines.121  Their proposal uses the 
existence of free software as an illustration that alternative 
business models are viable, but unfortunately it fails to make the 
point of how to translate OSS licensing ideals into the 
pharmaceutical industry.  Although Hubbard and Love’s argument 
may not connect directly with OA models, their suggestion is 
important because they propose workable ways to fund the basic 
research and to generate incentives to companies to distribute their 
intellectual property to the public, which would be released 
through open licenses.  But the question remains, which open 
licenses?  
The answer to the question of licenses may lie in the 
aforementioned CAMBIA project.  One of the most important 
parts of the objectives of CAMBIA is the use of open source ideals 
to generate a protected commons for researchers in the life 
sciences.  This is done through a couple of licenses—the BiOS 
Plant Enabling Technology License and the BiOS Genetic 
Resource Technology License.  These schemes can be used for 
specific types of patented material.  According to the project, the 
licenses work like this: 
Instead of royalties, BiOS licensees must agree to legally binding 
conditions in order to obtain a license and access to the protected 
commons.  These conditions are that improvements are shared, and that 
licensees cannot appropriate the fundamental “kernel” of the 
technology and improvements exclusively for themselves.  Licensees 
                                                 
120 Science Commons, Welcome to Science Commons, 
http://creativecommons.org/projects/science/proposal. 
121 Tim Hubbard & James Love, A New Trade Framework for Global 
Healthcare R&D, http://www.pubmedcentral.nih.gov/picrender.fcgi?artid= 
340954&blobtype=pdf. 
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obtain access to improvements and other information, such as 
regulatory and biosafety data, shared by other licensees.  To maintain 
legal access to the technology, licensees must agree not to prevent other 
licensees from using the technology in the development of different 
products.122  
The core concept of the BiOS Licenses is that they will be able 
to provide patented research with a permissive license that operates 
within OSS and open access principles.  However, this is easier 
said than done, and the existing drafts demonstrate just how 
difficult it is to word open source patent licenses.  Earlier drafts 
consisted of a single document that covered different types of 
patented technologies, particularly “Crop Molecular Enabling 
Technologies and associated patents, patent applications, know-
how, data, materials, and business, technical, economical and 
manufacturing information.”123  However, the complicated nature 
of the subjects prompted a forking of the license to cover two 
different technologies, such as plant-enabling technologies and 
genetic resources technologies.  While the subject and the specific 
application of both licenses are different, the legal principles and 
structure of both are the same, so they will be covered in the same 
way.  
The first important common element of the licenses is that the 
patent owner always retains control over the technology, and what 
is established is a permissive chain of distribution.  However, there 
is a possibility that that the licensor could be a licensee himself.  
The reason for this is because the BiOS Licenses contain a viral 
clause that allows licensees to sub-license the material, as long as 
the same rights that are contained in the license are preserved in 
the vertical agreement.124  Paragraph 2.1 is the license grant, which 
gives licensees:  “a worldwide, non-exclusive, royalty-free right 
and license to make and use the IP & Technology for the purpose 
                                                 
122 CAMBIA, Biological Innovation for Open Science, About BiOS 
(Biological Open Source) Licenses, http://www.bios.net/daisy/bios/398. 
123 CAMBIA, Biological Innovation for Open Science, About BiOS 
(Biological Open Source) Licenses, supra note 122, at BIOS License version 
1.1.   
124 CAMBIA, Biological Innovation for Open Science, About BiOS 
(Biological Open Source) Licenses, supra note 122, at para. 3.1 and subsections 
of both licenses.  
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of developing, making, using, and commercializing BiOS Licensed 
Products without obligation to CAMBIA, including a right to 
sublicense . . . .”125 
Similarly, improvements to the patented technology are 
allowed as long as those are communicated to licensor, along with 
all improvement patent applications.126  When compared to existing 
open source and open access licenses, the elements and clauses 
present in the BiOS License make it akin to a CC Attribution 
Commercial Share Alike license.  
This is a worthwhile effort to create a viable “open source” 
license for patented materials.  However, even in its draft stages it 
is easy to see that the language seems stretched and unclear in 
many instances—something that could turn away some potential 
licensors who could find the complex explanation of the terms and 
conditions difficult to navigate.  Another question that arises from 
the draft is that it is not very clear what would be the role of the 
initial licensor and his place in a lengthy chain of sub-licensees.  
Paragraph 2.1.2 for example, states that:   
BiOS LICENSEE shall be responsible to ensure in said sublicenses that 
any Improvements produced by sublicensees are considered to be 
Improvements hereunder and that such sublicenses require the 
performance of all applicable obligations due to CAMBIA and other 
BiOS Licensees under this Agreement and any associated Agreements.  
BiOS LICENSEE shall provide a list of sublicensees to CAMBIA in 
writing at least once a year, which CAMBIA is entitled to post in 
CAMBIA’s Protected Commons website (BioForge) or make available 
to BiOS Licensees.127 
Does this really mean that the sub-licensee has some duty of 
care with regards to the actions of subsequent sub-licensees?  How 
can such responsibility be exercised?  Does this give the licensee 
the same rights and obligations as the licensor?  What about the 
obligation to notify the licensor of any improvements?  It would 
                                                 
125 CAMBIA, Biological Innovation for Open Science, About BiOS 
(Biological Open Source) Licenses, supra note 122, at para. 3.1 and subsections 
of both licenses. 
126 CAMBIA, Biological Innovation for Open Science, About BiOS 
(Biological Open Source) Licenses, supra note 122, at para. 3.2 of both licenses.  
127 CAMBIA, BIOS Plant Enabling Technology License, http://www.cambia. 
org/daisy/PELicense/751/382.   
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seem that this would fall into the obligations of the sub-licensee.  
Is the sub-licensee in any obligation to notify the original licensor?   
It has been pointed out that the BiOS License is a work in 
progress and requires more fine tuning to be ready for 
consumption, so no further analysis of the drafts is wise at the 
moment when the final texts may change considerably in the near 
future.  Nevertheless, the draft licenses as they exist are 
tremendously complex, they represent a considerable legal 
document, which small and medium research facilities are 
supposed to sign to with little or no legal assistance.  The patent 
filed is subject to minute legal technicalities, and adding a 
complicated license to the equation may increase the legal 
uncertainty that already exists.  Research centres may be tempted 
to simply stay away from all open licensing efforts to reduce their 
liabilities.  But there are other inherent problems with patent 
licensing that make the porting of OSS extremely unlikely.  
3.  Trouble with Patents 
The difficulties with the one existing patent license scheme and 
the lack of other open science licenses indicates that there appears 
to be an inherent problem in porting a licensing model that has 
been designed to work with copyright into a system that would 
have to work with patents.  
There can be little doubt that patents offer the strongest short-
term protection of technologies emanating from costly scientific 
research.128  It has several advantages in order to protect certain 
technologies, particularly because some types of research may 
produce outputs that would not be suitable for copyright 
protection.  While this is precisely how the commercial world 
operates, those interested in making their work available to the 
public under some sort of open license model will have to do it by 
protecting their work, as the entire system is based on the threat of 
infringement suits brought against those who had not shared the 
work according to the required clauses.  
                                                 
128 See Mansfield, supra note 4. 
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The problem then for some institutions wanting to release their 
research is that they will have to obtain a patent in order to license 
it.  This can prove to be an expensive endeavor.  Some studies 
estimate that an average biotechnology patent application could 
cost an average of $7,500 in the United States alone.129  Because 
patents must be applied separately in each jurisdiction where they 
will be exploited,130 the costs for a small research institution could 
be prohibitive.  Even when the patent has been obtained, the 
enforcement of patents is where the costs are steeper.  The cost of 
defending a patent in the United States where the dispute is less 
than a million dollars can range from $300,000 to $750,000.131  
This means that even if a research institution obtains a patent to 
protect their research, the right holders would find it extremely 
expensive to defend their intellectual property against misuse—
particularly considering that those likely to use open source 
licenses may be small research institutions, or even individual 
researchers.132  The problem would be more pronounced for 
researchers in developing countries, as they would possibly have to 
enforce patents abroad.  
The sheer costs involved could be enough to dissuade small 
and medium research facilities to stay clear of the potential 
liabilities involved with the patent system, and continue releasing 
information through more traditional means.  Nevertheless, there 
may be a viable solution for the problem of the enforcement of 
patents held by individual organisations.  The problem of 
enforceability of OSS licenses is similar to what has been 
described in the previous paragraphs.  In software, many small 
software developers do not have the resources to enforce their 
copyrights.  For that purpose, the FSF recommends that all those 
                                                 
129 For more about the economics of the patent system, see ADAM JAFFE & 
JOSH LERNER, INNOVATION AND ITS DISCONTENTS:  HOW OUR BROKEN PATENT 
SYSTEM IS ENDANGERING INNOVATION AND PROGRESS, AND WHAT TO DO 
ABOUT IT, 64–69 (2004).  
130 There are, however, some ways around this, such as the existence of the 
European Patent Office, and the tools provided by the Patent Cooperation Treaty 
(“PCT”).  
131 JAFFE & LERNER, supra note 129.  
132 This assumption is an extrapolation from what is taking place in the use of 
open licenses in software and the creative industries.  
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programmers using their licenses should assign copyright of their 
works to the FSF because in that way they can enforce the license 
better in case of infringement.133  This scheme could be replicated 
in open science licenses, and has been accepted by CAMBIA as 
one of its potential roles by stating that BiOS will serve as “a 
collective defense of the commons and non-assertion of IP rights 
against other members of the commons.”134  Therefore, collective 
organisations could be in charge of the enforcement of research 
held by individuals.  
Another possible problem for the use of open licenses of 
patented technology is that it could be argued that open licenses 
are incompatible with prevalent patent policy goals.  An often 
stated goal of a patent system is to encourage the distribution of 
inventions through the utilitarian justification that allows for the 
economic reward.135  An open license model might clash with this 
objective because it would stop inventors from being able to 
economically recuperate investments in future research related to 
the patented one, particularly if a non-commercial viral license is 
used.  For example, imagine a patented gene sequence that has 
been licensed through a copyleft license containing non-
commercial viral restrictions.  Researchers who would want to 
patent improvements based on the licensed sequence and then 
exploit them commercially may find that they would be in breach 
of their licenses, as they would not be able to sub-license their 
work commercially because of the viral restrictions.  But what if 
those researchers incurred considerable expenses to produce the 
improvements?  They would have to license their research using a 
non-commercial clause as well, which would defeat the utilitarian 
justification for patents.  The BiOS License does not appear to 
have this problem because it allows commercial use of the patented 
technology, so there may be a case that there cannot be a 
non-commercial open license for patents.  
                                                 
133 Eben Moglen, Why the FSF gets copyright assignments from contributors, 
http://www.gnu.org/copyleft/why-assign.html. 
134 Biological Innovation for Open Science, Frequently Asked Questions—
BIOS Licenses, http://www.bios.net/daisy/bios/BiOS_licenses/bios_license_ 
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The apparent incompatibility of the patent system with open 
source is well known in the groups that advocate for its 
implementation.  The statement of purpose of the Science 
Commons project enumerates some of the problems faced by the 
project in trying to translate the CC ideals into working licenses for 
works that rely on patent protection.136  The Science Commons 
proposal goes as far as to point out that “[m]any of the things that 
we have learned in forming the Creative Commons do not translate 
completely to the world of science policy.  We dealt primarily with 
copyright—here the issues would also involve patent and trade 
secret.”137  
The potential incompatibility between patents and open source 
licenses is difficult to resolve.  Even with the early drafts of the 
BiOS Licenses, the nature of the patent system seems to offer 
insurmountable obstacles to the possible adoption of a viable open 
science license dealing with patented technology.  Those industries 
that are willing to incur the cost of expensive research will want to 
see their efforts rewarded, and a large patent portfolio will give 
research-heavy institutions an excellent bargaining position when 
dealing with other competitors within the industry.  The race to 
decode the human genome has served to demonstrate that there are 
significant economic interests at play, and this is a fact that will not 
go away overnight.  This is why the best option for smaller 
research facilities and public interest oriented institutions is to 
disseminate works through releases into the public domain.  This 
type of dissemination has the effect of widening the accessibility of 
the research by other small industries.  Another effect of the 
release of materials into the public domain would be to pre-empt 
future patent applications, because the research has already been 
made public.  Eisenberg explains this tactic:    
In addition to making it difficult for publicly-funded investigators and 
their institutions to file timely applications for patents, the Bermuda 
rules also lead to the prompt creation of “prior art” that could 
potentially defeat patent claims based on similar DNA-sequencing 
                                                 
136 Joy Davidson, Digital Curation Centre (DCC), Creative Commons:  
Establishing a Science Commons, http://creativecommons.org/science/about/ 
scbackground. 
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efforts in the private sector.  No one can get a patent on something that 
was already publicly disclosed before the patent claimant discovered 
it.138 
Despite this seemingly watertight solution, there is still a real 
potential that the information that has been made available for free 
could be copied and then used to make patent applications about 
that same material.  The chaotic state of patent applications in 
areas such as software and biotechnology139 provides a warning 
that patent offices cannot be trusted in identifying whether a patent 
application is innovative, or if it is based on significant prior art.  
It would be fair to assume that there are too many problems, 
and it could be suggested that perhaps open science should be 
scrapped—at least in open science for patents.  The lack of licenses 
at the moment makes the possible implementation difficult, while 
the few efforts that have been proposed still seem to fall short.  
Even the strongest proponents of open science and open 
biotechnology recognise that the movement cannot go forward 
without viable licenses.  Hope comments that:   
Key issues for advancing the open source biotechnology analysis will 
be developing open source patent licenses and other licenses 
appropriate for biotechnological subject matter, assessing the 
importance of higher capital costs in biotechnology development and 
establishing whether or not there exist secondary markets for 
biotechnology services or other commercial offerings that might 
support business models along the lines that have proved successful in 
the software context.140 
It is perhaps time to look at different options.  Those who 
believe in ensuring wider access to scientific research and 
technology should not be daunted by the difficulties encountered, 
as there may be other solutions that can provide a viable manner to 
                                                 
138 Rebecca Eisenberg, The Public Domain in Genomics (2000), 
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Patent Protection Be Considered for Computer Software-Related Innovations, 7 
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harness the creative and developmental strengths of the open 
source model with other ways of dissemination.   
V. SPECIFIC PROPOSALS 
Apart from the CAMBIA License, the tackling of the patenting 
problem is short in suggestions, as most of the proponents of the 
open science and open biotechnology solutions for scientific 
research usually fail to even tackle the question of the potential 
problems presented by patents.141  The solution to the problem may 
not be in the drafting of new complicated licenses, but in looking 
elsewhere for inspiration as to new manners of allowing wider 
access to patented technologies.  
In this line, Cukier has suggested that this is not an issue of 
licenses, but rather suggests that the patenting problems could be 
overcome through changes in government policy by applying 
existing national interest patent defenses that are already in use in 
the United States in the area of defense and health.142  He 
comments that:  
US-funded research enables the government to use the resulting 
technology on a royalty free basis.  In the case of the Bayh-Dole Act, 
the government has ‘march-in’ rights to take control of a patent it does 
not believe it being sufficiently exploited.  More broadly, the US and 
its contractors can’t be prohibited from using patented technology as a 
matter of law . . . .143   
However, this proposal seems to fall short, as it would be very 
difficult to convince governments in today’s IP protectionist 
environment that there should be some sort of public policy that 
permits the licensing of some works.  
Another novel solution would be to continue using the tried 
and tested OA and OSS licenses, but to change the clauses to read 
more generically.  For example, instead of using “copyright,” the 
licenses could use “intellectual property,” which would cover 
                                                 
141 Some examples have already been mentioned.  For other examples, see 
Stephen Maurer, Arti Rai & Andrej Sali, Finding Cures for Tropical Diseases:  
Is open source an answer, http://ist-socrates.berkeley.edu/~scotch/ PLOS.pdf.  
142 See Cukier, supra note 12.    
143 See Cukier, supra note 12.    
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patents.  However, this seems like an ad hoc patch that fails to 
provide a real answer to the problems highlighted.  This could be 
solved by using existing software licenses that mention patents.  
There is one such license:  the Apache License (version 2.0),144  
which contains a patent assignment clause that reads:  
Subject to the terms and conditions of this License, each Contributor 
hereby grants to You a perpetual, worldwide, non-exclusive, no-charge, 
royalty-free, irrevocable (except as stated in this section) patent license 
to make, have made, use, offer to sell, sell, import, and otherwise 
transfer the Work, where such license applies only to those patent 
claims licensable by such Contributor that are necessarily infringed by 
their Contribution(s) alone or by combination of their Contribution(s) 
with the Work to which such Contribution(s) was submitted.  If You 
institute patent litigation against any entity (including a cross-claim or 
counterclaim in a lawsuit) alleging that the Work or a Contribution 
incorporated within the Work constitutes direct or contributory patent 
infringement, then any patent licenses granted to You under this 
License for that Work shall terminate as of the date such litigation is 
filed.145   
This seems like a viable possibility, as Apache is the dominant 
web server around the world, with seventy percent of all websites 
on the net served by Apache software.146  The data suggests that a 
direct translation of the Apache license to the realm of patented 
technology would be possible.  However, there should be a 
cautionary word regarding the Apache License, and it is the fact 
that it is not the predominant open source license.  Out of more 
than 64,000 open source projects listed in the SourceForge portal, 
only 344 use this license.147 
Recent developments have suggested that there may be another 
way, and that strict licenses are not needed to provide a common 
pool of accessible scientific data and technology.  IBM has made 
the headlines of every major technology-related news publication 
                                                 
144 The license can be found at Open Source, Apache License, version 2.0., 
http://www.opensource.org/licenses/apache2.0.php. 
145 Id.   
146 According to Netcraft’s web server survey for March 2005.  See Netcraft, 
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by stating that it will not enforce 500 software patents that it owns 
if they are used by open source software projects.148  This 
unprecedented move has been achieved through a clever use of 
contract law.  IBM has published a legally-binding promise not to 
enforce a number of their patents to those software projects that are 
released to the public through a license approved by the Open 
Source Institute.149  This element of IBM’s pledge is very 
important, as it gives a tight definition of what will be an open 
source project.  The definition reads:   
Open Source Software is any computer software program whose source 
code is published and available for inspection and use by anyone, and is 
made available under a license agreement that permits recipients to 
copy, modify and distribute the program’s source code without 
payment of fees or royalties.  All licenses certified by opensource.org 
and listed on their website as of 01/11/2005 are Open Source Software 
licenses for the purpose of this pledge.150 
The document goes on to promise that IBM will not assert any 
of the listed patents in the United States, or its counterparts 
worldwide, against open source projects, defined as above.151  The 
document ends with a list of the 500 patents.  This announcement 
should be met with some skepticism, as IBM has a considerable 
software patent portfolio, and was awarded more than 3000 patents 
in 2004 alone.152  One should also be skeptical about the possible 
legal validity of such promise.  
The main question about the validity of the pledge is centred 
on the question of its classification within contractual law.  In this 
document, IBM is making a unilateral promise that stands on the 
assumption that it can be met by those who qualify as an open 
source developer.  This promise does not require an obligation per 
se, it simply promises not to sue a group of people that fulfill 
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2004, http://www.itfacts.biz/index.php?id=P2370.  
362 N.C. J. L. & TECH. [VOL. 7: 321 
certain characteristics.  In this manner, it is not so different than a 
retailer that promises to give free CDs to those who bring a coupon 
to their store.  The issue of unilateral promises is an area of the law 
that varies from one jurisdiction to another.  In some Common 
Law systems, the question of unilateral promises has often been 
dealt with as an issue of contract formation and consideration.153  
However, the landmark case of Carhill v. Carbolic Smoke Ball 
Company154 established that a unilateral promise that is accepted 
through the performance of an act is valid.  Scotland does not have 
a problem with acceptance; therefore unilateral promises are much 
less of an issue and have to be considered generally valid.155  Other 
European countries have different rules for the acceptance of 
unilateral promises,156 but countries like Germany157 and France158 
allow some models of obligations arising from unilateral promises.  
This tends to give strength to the validity of IBM’s promise.  
IBM’s non-enforcement promise is a very practical and 
seemingly valid solution that can be applied to all other sorts of 
patents, and it could prove to be an effective tool to solve the 
problematic application of OSS models to patented technologies.  
This could work for individual scientists or research institutions 
that are interested in maintaining their intellectual property, but 
that want to allow access to their patented material to specific 
recipients.  These institutions could publish their own promise not 
to assert their patent portfolio, or a selected list of patents, as long 
as the users fall into a specified category of beneficiaries.  It is 
important that the patent owner identifies clearly the intended users 
of the technology, and defines it unequivocally in the document.  A 
                                                 
153 See, e.g., Paul Mitchell & John Phillips, The Contractual Nexus:  Is 
Reliance Essential, 22 OXFORD J. LEGAL STUD. 115, 118–24 (2002).   
154 [1893] 1 QB 256 (C.A.).   
155 There are a few exceptions, such as the requirement that the promise 
should be in writing.  For more about promises in Scotland contract law, see 
HECTOR MACQUEEN & J.M. THOMSON, CONTRACT LAW IN SCOTLAND, 63–69, 
(2000). 
156 For more about European applicability of unilateral promises, see THE 
ENFORCEABILITY OF PROMISES IN EUROPEAN CONTRACT LAW, (J. Gordley ed., 
Cambridge Univ. Press 2001). 
157 Burgerliches Gesetzbuch [BGB] § 657.   
158 As shown in Cass. Civ. 1re, (Oct. 16, 1995).  
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promise that allows use in developing countries would be useless, 
unless it is accompanied by a clear definition of what constitutes a 
developing country, and what sort of users in those countries 
would benefit from the pledge.  A possible clause could thus read:  
“this pledge will benefit researchers based in a Least Developed 
Country as defined by the United Nations Conference for Trade 
and Development;” or “for the purpose of this promise, developing 
country will be defined as a country that is listed as having low 
human development in the 2004 Human Development Report by 
the United Nations Development Programme.”  Another important 
element to add is that the patent owner could generate a web form 
where users who fall into the definition could register as such, 
which would have the added benefit that the owner would have a 
better idea of who is using the technology.  
One of the main advantages of the use of a unilateral promise is 
that it helps to focus the access to scientific research to those who 
the patent owner would not consider to be a commercial threat or 
potential competition, which would erase some of the concerns 
about the possible incompatibility of open source models with the 
expenses and commercial value of research.  This solution is not a 
licensing scheme; therefore, it eliminates some of the more 
complex contractual chains of distribution that can be found in 
viral contracts.  Researchers could also gain in the knowledge that 
there will be a certain amount of knowledge that can be used 
without fear of infringement.  
VI. DRAFT PROMISE 
Preamble 
[This space can be used to indicate the purpose and the 
rationale behind the promise] 
Definitions 
[This space will contain a series of strict definitions of the 
beneficiaries.  Some examples are provided] 
“Technology”:  the list of patents included in the Annex.  
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“Owner”:  The patent owner, [INSERT NAME].   
“Beneficiary”:  Any organisation that is a listed participant 
of BioForge projects as of [INSERT DATE].  
Promise 
The Owner hereby promises not to enforce any of the listed 
Technology against Beneficiaries that have registered their 
intent to use the Technology at the following address [INSERT 
FORM ADDRESS].   
Warranty 
The Owner certifies that the Technology is owned by 
him/her [or that it has specific permission to issue the promise].  
The Owner also certifies that the Technology is not subject to 
litigation as of [INSERT DATE].  The Owner presents the 
Technology “as is,” and makes no warranty as to the accuracy 
of the information contained in the patent application.  
Limitation of Liability 
Subject to any liability which may not be excluded or 
limited by law, the Owner will not be held liable for incidental, 
consequential, or indirect loss or damage howsoever and 
whenever caused to the Beneficiary. 
Annex 
[Table of patents, listing patent number, awarding office, 
beneficiary and title (or brief description)] 
VII. CONCLUSION 
The issue of access to scientific research is becoming one of 
the most important issues of our time.  The direction of the flow of 
knowledge rests greatly on the problem of the ownership of 
technology.  One of the grandest ideas in recent years is the use of 
intellectual property tools to protect certain parts of human 
knowledge, something that is managing to generate shared 
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knowledge, a common pool of technology and research that can be 
accessed by all; a common space where the information flows with 
fewer restrictions than in an entirely proprietary model.   
This common space has already been experimented with and 
explored within the free software and open source software 
communities.  The non-proprietary software experiment has 
demonstrated that open development models are viable and 
sometimes even commercially successful.  Amongst these models, 
one of the most interesting licenses is that offered by so-called 
copyleft licenses, those licenses that allow software to be 
transferred with the insurance that the source code will remain 
open, with the caveat that anyone who redistributes the software, 
with or without changes, must pass along the freedom to further 
copy and change it.  
However, software development is not the only area in which 
this licensing model could be applied.  The viral nature of copyleft 
licenses has generated a considerable amount of interest in circles 
that transcend software development.  The idea of sharing 
materials is not new, and has been made more evident by the 
chaotic and sometimes anarchic nature of the Internet.  However, 
shared materials tend to suffer from the possibility of third parties 
who use the freely acquired information to turn them into 
proprietary works.  That is why many different organisations are 
turning to the copyleft model to protect works that are being freely 
shared online.  
This article has explored the application of non-proprietary 
software licenses to scientific research—particularly academic 
publications, scientific databases, and patented technologies.  To 
do this, several different licensing models have been explored.  It 
is clear that copyright materials are well suited for this experiment, 
and the area of scientific publications shows special promise for 
the future.  Unfortunately, other types of scientific outputs present 
more challenges to those involved.  Costly research and 
development have produced entire fields of study that are not 
suitable to adopt the open source ideals.  Although the trailblazing 
efforts of CAMBIA, HapMap and the BiOS Licenses must be 
applauded and recognised, the author feels that there is much to be 
366 N.C. J. L. & TECH. [VOL. 7: 321 
done to ensure access to expensive technology to the widest 
possible audience.  IBM’s unilateral promise gives researchers a 
model to emulate to ensure this objective.  It is feasible to apply 
this document to almost all investigation efforts that result in a 
patent.  
The author recognises that this is just a draft proposal, but it is 
hoped that others can continue to add to this idea if it is found to be 
useful.159  In the best spirit of the Bazaar, and paraphrasing Linus 
Law, given enough eyeballs, all license bugs are shallow. 
                                                 
159 Comments about this draft are welcome, please send them to 
a.guadamuz@ed.ac.uk.  
